Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01532622
Other study ID # 2011-0218
Secondary ID
Status Completed
Phase N/A
First received January 30, 2012
Last updated October 18, 2013
Start date January 2012
Est. completion date October 2013

Study information

Verified date October 2013
Source University of Mississippi Medical Center
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the impact of blueberries on uric acid in patients with hyperuricemia that are not receiving uric acid pharmacotherapy. The central hypothesis the investigators propose is that daily blueberries added to a pre-existing diet will promote uric acid lowering and improve quality of life without detriment to vital signs.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date October 2013
Est. primary completion date October 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 88 Years
Eligibility Inclusion Criteria:

- 18 years or older

- Uric acid > 6.0 mg/dL

Exclusion Criteria:

- Current moderate-to-severe symptomatic gout

- Currently receiving gout pharmacotherapy

- Current participation in another clinical trial

- Documented non-compliance or consistent missed appointments

- Women who are pregnant or nursing

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Blueberry Powder
Patients will take 30 grams of blueberry powder daily for up to 30 days
Other:
Placebo Powder
Patients will take 30 grams of placebo powder daily for up to 30 days.

Locations

Country Name City State
United States University of Mississippi Medical Center Jackson Mississippi

Sponsors (2)

Lead Sponsor Collaborator
University of Mississippi Medical Center U.S. Highbush Blueberry Council

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline and Placebo in Uric Acid Level in Patients Randomized to Treatment Group Percent change in uric acid level from baseline after 30 days of treatment with blueberry powder. Since this is designed as a crossover trial, baseline could represent uric acid level at the beginning of the study or after at least a 2-week washout period following placebo administration. Baseline, ~30 days later No
Secondary Blood Pressure Percent change and absolute change of blood pressure from baseline and placebo Baseline, ~30 days, ~45 days, ~75 days No
Secondary Body Weight Percent change and absolute change of body weight from baseline and placebo Baseline, ~30 days, ~45 days, ~75 days No
Secondary Quality of Life Quality of life will be assessed using the Health Assessment Questionnaire-Disability Index (HAQ-DI) Baseline, ~30 days, ~45 days, ~75 days No
See also
  Status Clinical Trial Phase
Recruiting NCT05434858 - Imagery as Biomarker of Gout N/A
Completed NCT04060173 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 Phase 1
Recruiting NCT05504083 - Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients Phase 2
Completed NCT04966325 - Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects Early Phase 1
Completed NCT01407874 - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency Phase 2
Completed NCT00995618 - Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia Phase 2
Completed NCT00288158 - Primary Prevention of Hypertension in Obese Adolescents Phase 2
Terminated NCT04987294 - Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease Phase 2
Completed NCT04236219 - ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers Phase 1
Completed NCT06189404 - Effect of Tigulixostat on the Pharmacokinetics of Theophylline Phase 1
Recruiting NCT05586958 - Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients Phase 3
Recruiting NCT06084585 - The Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia N/A
Recruiting NCT06056570 - Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia Phase 1/Phase 2
Not yet recruiting NCT04586803 - Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers Phase 1
Completed NCT02959918 - Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid Phase 2
Not yet recruiting NCT02944214 - Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients N/A
Completed NCT02557126 - Study of URC102 to Assess the Safety and Efficacy in Gout Patients Phase 2
Active, not recruiting NCT01021241 - Safety and Efficacy Study of Intravenous Uricase-PEG 20 Phase 1
Completed NCT00756964 - Lowering Serum Uric Acid to Prevent Acute Kidney Injury Phase 2
Terminated NCT00607152 - Rasburicase (Fasturtec) Registration Trial Phase 3